E. Gerald Kay - 30 Jun 2023 Form 5 Insider Report for INTEGRATED BIOPHARMA INC (INBP)

Reporting relationship: Executive Chairman & President, Director, 10%+ Owner
Issuer ticker: INBP
Reported as of: 30 Jun 2023
Net transaction value: $0
SEC form: 5
Accepted by SEC: 16 Nov 2023, 16:13:09 UTC
Prior SEC filing: 10 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Christina Kay

Key filing fact

E. Gerald Kay filed Form 5 for INTEGRATED BIOPHARMA INC (INBP) on 16 Nov 2023.

Key facts

This page summarizes E. Gerald Kay's Form 5 filing for INTEGRATED BIOPHARMA INC (INBP).
6 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 16 Nov 2023, 16:13.

Change

Previous filing in this sequence was filed on 10 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INBP transaction

Common Stock

Will/Inheritance

Transaction value: $0
Shares: -4,299,533
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Mar 2023
Ownership: Direct

INBP transaction

Common Stock

Will/Inheritance

Transaction value: $0
Shares: -853,022
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Mar 2023
Ownership: As sole member of LLC or Trustee of Trusts
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBP transaction Derivative

Stock Option (right to buy)

Will/Inheritance

Transaction value: $0
Shares: -150,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.2300
Footnotes: F2, F3

INBP transaction Derivative

Stock Option (right to buy)

Will/Inheritance

Transaction value: $0
Shares: -100,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $0.7200
Footnotes: F2, F3, F4

INBP transaction Derivative

Stock Option (right to buy)

Will/Inheritance

Transaction value: $0
Shares: -65,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $1.04
Footnotes: F2, F3, F5

INBP transaction Derivative

Stock Option (right to buy)

Will/Inheritance

Transaction value: $0
Shares: -100,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $0.4500
Footnotes: F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

E. Gerald Kay is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Includes (i) 819,628 shares registered to the name of EGK LLC, an entity the Reporting Person was the sole member of and (ii) 16,697 shares held in each of the Riva Grantor Trust and Christina Kay Grantor Trust whereas the Reporting Person was the Trustee.

Footnote F2

The option vested over three years beginning of the first year anniversary noted herein.

Footnote F3

Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death.

Footnote F4

Includes 33,333 shares that were not vested at the time of the Reporting Person's passing.

Footnote F5

Includes 43,333 shares that were not vested at the time of the Reporting Person's passing.

Footnote F6

None of the Options were vested at the time of passing of the Reporting Person.